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LYG for Estonia. Sensitivity analyses showed that time horizon, discounting and
follow-up cost of stroke are sensitive factors. Difference in co-payment for workers
and retired patients (Estonia) marginally impacted ICERs. Probabilistic sensitivity
analysis showed that the probability for O-3EE to be cost-effective is higher than
95% in Estonia (threshold €32,000/LYG). One-way sensitivity analyses showed
strong robustness in Ireland (threshold €20,000/QALY). CONCLUSIONS: The incre-
mental cost-effectiveness ratios indicated that adding 1g O-3EE to standard treat-
ment in secondary prevention post-MI was in the range likely to be considered
cost-effective in Ireland and Estonia.
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OBJECTIVES: To compare the incremental cost-effectiveness ratio (ICER) and in-
cremental cost-utility ratio (ICUR) of the angiotensin II receptor antagonist Azilsa-
tan vs current treatments of the same drug class as valsartan, telmisartan, losartan
and irbesartan. METHODS: Cost-effectiveness and cost-utility analysis were con-
ducted using a Markov model with a 35-year temporal horizon for patients over the
age of 45 and diagnosed with systemic arterial hypertension to calculate the ICERs
of each treatment. The model adopts the Mexican public health institutions’ per-
spective. Four health states were incorporated: alive and healthy, hypertensive
with non-fatal acute myocardial infarction (AMI), hypertensive with non-fatal
stroke and death. Transition probabilities were calculated based on the national
risk of having a stroke or AMI and the probability of having a vascular complication
depending on blood pressure levels (in mmHg). Costs and effectiveness data were
taken from health institutions, producer pharmaceutical companies or extracted
from published literature. Outcome measures included ICER and ICUR. Cost-effec-
tiveness was determined according to the 1GDP/capita threshold established by
the National Health Council in Mexico. RESULTS: Azilsartan was found to be dom-
inant when compared with telmisartan, valsartan and irbesartan. Azilsartan was
also more effective when compared with losartan (10.76 vs. 10.47 life years gained)
although more costly (USD$ 6,118.92 vs. USD$ 5,192.71). The ICER was USD$
3,202.84 per life year gained. According to the cost-utility analysis, the ICUR per
quality-adjusted life year gained was USD$ 3,458.09. CONCLUSIONS: The ICER and
ICUR are well below 1GDP (USD$ 9,350.07) per capita versus losartan. Both azilsar-
tan and losartan were found to be dominant in comparison with the other included
treatments. Azilsartan is therefore a very cost-effective intervention for the Mexi-
can population over 45 with systemic arterial hypertension.
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OBJECTIVES: Transferring cost-effectiveness information between geographic do-
mains offers the potential for more efficient use of analytical resources. However,
it is difficult for decison makers to know when they can rely on cost-effectiveness
evidence produced for another context. This paper explores the transferability of
economic evaluation results produced for one geographic area to another location
of interest, and outlines an approach to identify factors to predict when this is
appropriate. METHODS: We developed multilevel statistical models for the inte-
gration of published cost-effectiveness data to assess the impact of contextual
effects on country level; whilst controlling for baseline characteristics within, and
across, a set of economic evaluation studies. Explanatory variables were derived
from a list of factors suggested in the literature as possible constraints on the
transferability of cost-effectiveness evidence. We illustrated our approach using
published estimates of the cost-effectiveness of statins for the primary and sec-
ondary prevention of cardiovascular disease (CVD). 2094 estimates of the costs and
effects of statins were abstracted from 67 studies related to 23 geographic domains,
together with covariates on data, study and country level. RESULTS: The propor-
tion of variation at the country-level observed depends on the appropriate multi-
level model structure and never exceeds 15% for incremental effects and 21% for
incremental cost respectively. Key sources of variability are patient and disease
characteristics, intervention cost and a number of methodological characteristics
defined on the data level. There were fewer significant covariates on the study and
country levels. CONCLUSIONS: Our analysis suggests that variability in cost-effec-
tiveness data is primarily due to differences between studies, not countries. Fur-
ther, comparing different models suggests that data from multinational studies
severely underestimates country-level variability. Additional research is needed to
test the robustness of these conclusions on other sets of cost-effectiveness data,
and to further explore the appropriate set of covariates.
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OBJECTIVES: To evaluate health outcomes and costs of initiation with endothelin
receptor antagonists [ERA] monotherapy (ambrisentan or bosentan) followed by
sequential combination with phosphodiesterase-5 inhibitors [PDE-5] and prostan-
oids in the treatment of pulmonary arterial hypertension in Spain. METHODS: A
Markov model was developed based on New York Hearth Association functional
classes. Transition probabilities [TP] for ERA initiation were gathered from the
pivotal clinical trials. Outcomes were measured in quality-adjusted life years
[QALY]. A panel of 3 independent experts reached a consensus on patient manage-
ment based on clinical practice. Patients initiated treatment with either ambrisen-
tan or bosentan, and revised treatment every 12 weeks based on their health status
and previous medication records. A National Health System perspective was ad-
opted. Pharmacological costs and costs associated with very frequent adverse
events [AE] (i.e. edema and hepatic abnormalities) were included. Following a first-
order Monte Carlo simulation approach, 1,000 hypothetical patients were observed
in a temporal horizon of 60 weeks. This simulation was repeated 1,000 times.
RESULTS: Average (per-patient and year) pharmacological costs [95% CI] were
€35,550 [€34,944-€36,196] and €40,224 [€39,264-€41,212] for initiation with ambrisen-
tan and bosentan, respectively. Average costs associated with AE management
were €117 [€110-€124] and €171 [€160-€182], respectively. No clinically relevant dif-
ferences in average QALY were found: 0.6853 [0.6836-0.6870] and 0.6903 [0.6885-
0.6921], respectively. This agrees with published meta-analyses and a priori expert
judgment. Initiation with ambrisentan would bring about cost savings of €4,727
[€3,903-€5,620]. From a cost-minimization perspective, if the same TP were consid-
ered for both initiation alternatives, initiation with ambrisentan would provide
cost savings of €4,952 [€4,898-€5,007] (using ambrisentan’s TP) and €4,770 [€4,718-
€4,819] (using bosentan’s TP). CONCLUSIONS: Initiation with ambrisentan mono-
therapy followed by sequential combination with PDE-5 and prostanoids yields
comparable outcomes at lower costs than initiation with bosentan. These results
might be considered in hospital pharmacy budget allocation decision making.
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OBJECTIVES: To conduct an economic analysis of the risk assessment of VTE with
Thrombo inCode, a genetic platform, in patients with a pattern of VTE or a condi-
tion that suggests a hereditary component, compared with the standard methods
so far used (Factor V Leiden and prothrombin G20210A mutation). METHODS: A
Markov model was developed with 7 states of health (thrombophilia, no thrombo-
philia, VTE, major bleeding, intracranial hemorrhage, no intracranial hemorrhage,
and death). The predictive ability of VTE from the identification of thrombophilia
with Thrombo inCode and the standard method, was obtained from three studies
of the method validation performed in three different populations (3,661 patients
in total). It was assumed that patients with thrombophilia positively identified
undergo a preventive treatment of VTE, which involves both reducing the number
of VTE as the increase in major bleeding. The utilities and costs of Markov states
were obtained from the literature and Spanish sources. The analysis was done
from the National Health System perspective, for a time horizon of 5 years and
lifetime. An annual discount rate of 3.5% for costs and benefits was applied.
RESULTS: For a Thrombo inCode price of 290 €, this genetic platform would be the
dominant option for any time horizon from 5 years. The threshold price of
Thrombo inCode to reach the incremental cost-effectiveness ratio (ICER) threshold
generally accepted in Spain (30,000 €/QALY) would range between € 1,069 and €
1,284. Probabilistic analyses indicate that Thrombo inCode assessment is domi-
nant in the 97.2 to 98.6% of the tests, according to the selected population.
CONCLUSIONS: Thrombo inCode is a cost-effective genetic option in VTE risk as-
sessment compared with the standard method.
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OBJECTIVES: Limited pharmaceutical options are available for smoking cessation
interventions for smokers with a history of cardiovascular disease (CVD) in the
Netherlands. The objective of our study was to assess the cost-effectiveness of
varenicline versus nicotine replacement therapy (NRT) in such a population.
METHODS: A lifetime horizon Markov model was developed to compare the cost-
effectiveness of smoking cessation therapies from the health care provider per-
spective. Efficacy data (continuous abstinence rates) for each therapeutic option
was obtained from an indirect comparison of available clinical trials. The popula-
tion of smokers with cardiovascular disease was divided into three cohorts: those
with a history of coronary heart disease (CHD), stroke and peripheral vascular
disease (PVD). In the model, the cohorts are followed as they progress through
potential disease states including CHD, stroke, PVD, COPD, mouth cancer and lung
cancer. Transition probabilities depend on age (35-65, 65), gender and smoking
status (current, former or never smoker) allowing for variations in the patient
populations. Following the Dutch pharmacoeconomic research guideline, costs
and effect were discounted at 4% and 1.5%, respectively. Univariate and probabi-
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